You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 4
  • PO005LBA/#1579  A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-res…

Citation Tools

Article menu

Download PDFPDF

Plenary 01: Oral Abstract Presentations
AS11. Ovarian cancer
PO005LBA/#1579  A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009)
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
O’Cearbhaill R, Sill M, Duong H, et al
PO005LBA/#1579  A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009)
International Journal of Gynecologic Cancer 2023;33:A4.